GW Pharmaceuticals PLC (GWPH) CEO Justin Gover on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/12/20
GW Pharmaceuticals sells more of CBD-derived epilepsy drug than expected, stock risesMarket Watch • 05/11/20
GW Pharmaceuticals Q1 Results Will Provide Important Markers For The Coming YearSeeking Alpha • 05/05/20
GW Pharmaceuticals and Greenwich Biosciences Announce FDA Acceptance of sNDA Filing with Priority Review for EPIDIOLEX® (cannabidiol) in the Treatment of Seizures Associated with Tuberous Sclerosis ComplexGlobeNewsWire • 03/31/20
Why Biogen, GW Pharmaceuticals, and Vertex Pharmaceuticals Stocks Jumped TodayThe Motley Fool • 03/17/20
GW Pharmaceuticals submits Type II Variation Application to the European Medicines Agency (EMA) to expand the use of EPIDYOLEX®, (cannabidiol) oral solution, for the treatment of seizures associated with Tuberous Sclerosis Complex (TSC)GlobeNewsWire • 03/13/20
There Were Once 20 Pot Stocks With a $1 Billion Valuation or Higher. Only 8 Remain.The Motley Fool • 03/10/20
3 Ways to Benefit From the Cannabis Industry's Growth Without Taking on Much RiskThe Motley Fool • 03/06/20